CD8A and neoplasm: Because the antitumor effect of oncolytic virotherapy is short-lasting because the virus is eliminated by the innate and adaptive immune responses, we hypothesized that the paucity of CD103+ DCs at the tumor site restricted the expansion of tumor-specific CD8+ T cells and, therefore, limited the efficacy of the viroimmunotherapy treatment.